SynthesisBMC infectious diseases2025
Research mapping and comparative assessment of drug treatment regimens for brucellosis: a systematic review and network meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Pre-treatment IFN-γ levels are associated with chronic progression in patients with brucellosis: a retrospective study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThere are different treatment regimens for treating human brucellosis. This study aimed to evaluate the comparative effectiveness and ranking of different treatment regimens for human brucellosis through a systematic review and network meta-analysis (NMA).
methodsA systematic search was conducted in PubMed, ScienceDirect, Web of Science, and Embase to identify randomized controlled trials (RCTs) from their inception until February 1, 2023. Only RCTs comparing different treatment regimens for human brucellosis were included. The risk of bias was assessed using the Cochrane Risk of Bias tool. Consistency and heterogeneity were evaluated using Cochrane's I^2 and Q statistics. Our outcomes of interest include the "recovery" of patients with brucellosis following pharmacological treatment, as well as the "relative ranking" of the effectiveness of the studied treatment regimens compared to one another. Treatment effects were estimated using the relative risk (RR) effect size, while the P-score and Sucra was utilized to rank treatments in the NMA. A random-effects model was applied to account for between-study variability, and results were reported with 95% confidence intervals (CI).
resultsOut of 872 primary studies reviewed, a total of 32 studies were included in our network meta-analysis. The comparative effectiveness (measured by improvement) of the doxycycline (DOX) + streptomycin (SRT) + hydroxychloroquine (HYD) treatment regimen (RR:1.25, 95%CI: 1.07-1.45) is greater than other treatment regimens compared to DOX + rifampin (RIF) (RR:1) Following that, the DOX + STR + RIF and STR + ofloxacin (OFL) + RIF treatment regimens ranked second and third, respectively. The heterogeneity of the designs in our intervention network was estimated to be 37%, indicating low inconsistency within an acceptable range.
conclusionThe findings highlight the superior efficacy of triple-drug regimens, particularly those involving aminoglycosides, over dual-drug and monotherapy options. Our results confirm that DOX + STR + HYD is the most effective treatment regimens for human brucellosis. These new findings, when considering practical considerations, could inform the updating of clinical treatment protocols for human brucellosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.